Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California, USA.
Byers Eye Institute at Stanford, Stanford University School of Medicine, Palo Alto, California, USA
Br J Ophthalmol. 2020 Sep;104(9):1184-1189. doi: 10.1136/bjophthalmol-2019-315192. Epub 2020 Feb 7.
Retinal vein occlusion is the second-leading cause of vision loss by retinal vascular disease. Subthreshold micropulse laser therapy (SLT) is safer than conventional laser photocoagulation (CLP), yet existing reviews of its use for branch retinal vein occlusion (BRVO) are limited in scope. A literature search of PubMed, Google Scholar, Embase, Cochrane Library and ClinicalTrials.gov databases was conducted in August 2019 without restriction on language or publication date. Outcomes included changes in macular oedema (ME) and visual acuity (VA), and rates of complications or retreatments. Fourteen studies involving 315-405 eyes diagnosed with BRVO were evaluated. Treatment with SLT is associated with significant and durable reduction of ME and VzA as early as 1 month. SLT performs comparably with conventional photocoagulation and intravitreal injections (IVIs) of ranibizumab. Subthreshold laser therapy is safer and as effective as CLP for the treatment of ME associated with BRVO. SLT may be used in combination with anti-VEGF IVIs to enhance improvement in VA and ME resolution.
视网膜静脉阻塞是视网膜血管疾病导致视力丧失的第二大原因。阈下微脉冲激光疗法（SLT）比传统激光光凝（CLP）更安全，但现有的关于其用于分支视网膜静脉阻塞（BRVO）的综述在范围上受到限制。2019 年 8 月，我们在 PubMed、Google Scholar、Embase、Cochrane Library 和 ClinicalTrials.gov 数据库中进行了文献检索，没有对语言或出版日期进行限制。结果包括黄斑水肿（ME）和视力（VA）的变化，以及并发症或再次治疗的发生率。评估了 14 项涉及 315-405 只诊断为 BRVO 的眼睛的研究。早在 1 个月，SLT 治疗就与 ME 和 VzA 的显著和持久减少相关。SLT 与传统光凝和雷珠单抗玻璃体内注射（IVI）的疗效相当。对于与 BRVO 相关的 ME，阈下激光治疗比 CLP 更安全且同样有效。SLT 可与抗 VEGF IVI 联合使用，以增强 VA 和 ME 分辨率的改善。
